TNFR1 and TNFR2 are single-pass, type I transmembrane glycoproteins that are two distinct types of high­affinity cell surface receptors for TNF. Both receptors are the founding members of the TNF receptor superfamily (TNFRSF) and are designated TNFRSF1A and TNFRSF1B, respectively. The extracellular regions of both receptors contain 4 conserved cysteine­rich repeats that mediate the interaction with TNF. However their intracellular sequences have no homology, indicative of distinct signaling pathways. TNFR1 and TNFR2 form a heterocomplex on the cell surface that mediates the recruitment of adaptor proteins for signal transduction. Soluble truncated forms of TNFR1 and TNFR2 have been identified in human serum and urine, which can neutralize the biological activities of TNF. Whereas all cell types studied express TNFR1, TNFR2 expression is limited primarily to hematopoietic cells and cells of the immune system. TNFR2 mediates most of the metabolic effects of TNF.  TNFR2 binds with high affinity to TNF-α and approximately 5-fold lower affinity to TNF-β. The soluble form of TNFR2 is produced from the membrane form by proteolytic processing and is clinically used to treat moderate to severe rheumatoid arthritis (RA). In addition high plasma levels of soluble TNFR2 are associated with increased incidence of coronary heart disease.

TNFR1 and TNFR2 are single-pass, type I transmembrane glycoproteins that are two distinct types of high­affinity cell surface receptors for TNF. Both receptors are the founding members of the TNF receptor superfamily (TNFRSF) and are designated TNFRSF1A and TNFRSF1B, respectively. The extracellular regions of both receptors contain 4 conserved cysteine­rich repeats that mediate the interaction with TNF. However their intracellular sequences have no homology, indicative of distinct signaling pathways. TNFR1 and TNFR2 form a heterocomplex on the cell surface that mediates the recruitment of adaptor proteins for signal transduction. Soluble truncated forms of TNFR1 and TNFR2 have been identified in human serum and urine, which can neutralize the biological activities of TNF. Whereas all cell types studied express TNFR1, TNFR2 expression is limited primarily to hematopoietic cells and cells of the immune system. TNFR2 mediates most of the metabolic effects of TNF.  TNFR2 binds with high affinity to TNF-α and approximately 5-fold lower affinity to TNF-β. The soluble form of TNFR2 is produced from the membrane form by proteolytic processing and is clinically used to treat moderate to severe rheumatoid arthritis (RA). In addition high plasma levels of soluble TNFR2 are associated with increased incidence of coronary heart disease.

  

Product Details

 

Gene Symbol: TNFRSF1B; CD120b; p75; TBPII; TNFBR; TNFR1B; TNFR80; TNF-R75; p75TNFR; TNF-RII

 

NCBI Gene ID: 7133

 

Uniprot Entry: P20333

 

Construct Details: The recombinant human TNFR2-Fc fusion is expressed as a 460 amino acid protein consisting of Leu23 - Asp257 region of TNFR2 (UniProt accession #P20333)  and a C-terminal Fc from human IgG1, which exists as a dimer/tetramer under non-reducing conditions (see the gel image above).  

 

Source: Human cells stably expressing human TNFR2-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence:

        10         20         30         40         50         60 

LPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST 

        70         80         90        100        110        120 

YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK 

       130        140        150        160        170        180 

CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS 

       190        200        210        220        230        240 

TSPTRSMAPG AVHLPQPVST RSQHTQPTPE PSTAPSTSFL LPMGPSPPAE GSTGDTHTCP 

       250        260        270        280        290        300 

PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA 

       310        320        330        340        350        360 

KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 

       370        380        390        400        410        420 

VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY 

       430        440        450        460 

SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 

 

M.W.: Calculated molecular mass (kDa): 50.5; Estimated by SDS-PAGE under reducing condition (kDa): 75-85

 

Calculated PI: 7.15

 

Calculated extinction coefficients (M-1 cm-1, at 280nm):  61110

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBSpH7.4 (carrier & preservative free). The purified recombinant protein was labeled with Biotin (3-5 Biotin per molecule) using the standard procedure.

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to its ligand TNF and inhibits TNF-mediated biological activities including NF-κB activation and cytotoxicity in the mouse L929 fibrosarcoma cells.

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Science 248:1019 (1990).

2. Cell 78:681-692(1994)

3. Cell 104:487 (2001). 

4. Annu. Rev. Immunol. 19:163 (2001).

5. Science 296:1634 (2002). 

 

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL0059B-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.